Predictors of adverse events and early mortality after esophageal stent placement in a low resource setting: a series of 3823 patients in Kenya

Abstract

Background and study aims Dysphagia from esophageal cancer may be palliated with self-expanding metallic stents (SEMS). Controversy exists about the use of dilation before SEMS deployment.

Patients and methods We performed a retrospective cohort study of patients who had SEMS placement without fluoroscopy for palliation at Tenwek Hospital in Bomet, Kenya between January 1999 and April 2019. The primary outcome was any serious adverse event (AE) (chest pain, stent migration, perforation, bleeding, or all-cause mortality) within 30 days of the procedure. Various demographic and clinical characteristics, and procedural details, were examined as risk factors. Technical success, defined as correct SEMS placement, and clinical success, defined as dysphagia score improvement without 30-day mortality, were examined.

Results A total of 3823 patients underwent SEMS placement, with 2844 (74.4 %) placed in the second decade of the study. Technical and clinical success were achieved in 97.2 % and 95.5 %, respectively, with mean dysphagia scores improving from 3.4 (SD 0.6) to 0.9 (SD 1.3) post-stent placement. AEs occurred in 169 patients (4.4 %). AEs, specifically perforations, were associated with dilation to greater than 36F in the first decade. Perforation rates decreased from the first (4.1 %) to the second decade (0.2 %). Only 30% had complete 30-day follow-up data.

Conclusions SEMS placement is a safe, effective method of palliating malignant dysphagia, with low rates of AEs and 30-day mortality and high rates of clinical and technical success. Dilation can facilitate placement of SEMS without fluoroscopy but should not be performed above 36F due to the risk of perforation.

• References

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
• 2 Gibbs JF, Rajput A, Chadha KS. et al. The changing profile of esophageal cancer presentation and its implication for diagnosis. J Nat Med Assoc 2007; 99: 620
• 3 Wildi SM, Cox MH, Clark LL. et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004; 99: 1044-1049
• 4 Guyer DL, Almhanna K, McKee KY. Palliative care for patients with esophageal cancer: a narrative review. Ann Translat Med 2020;
• 5 White RE, Parker RK, Fitzwater JW. et al. Stents as sole therapy for oesophageal cancer: a prospective analysis of outcomes after placement. Lancet Oncology 2009; 10: 240-246
• 6 Spaander MC, Baron TH, Siersema PD. et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2016; 48: 939-948
• 7 Vermeulen BD, Siersema PD. Esophageal stenting in clinical practice: an overview. Curr Treatment Options Gastroenterol 2018; 16: 260-273
• 8 Knyrim K, Wagner H-J, Bethge N. et al. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 1993; 329: 1302-1307
• 9 Rodrigues-Pinto E, Ferreira-Silva J, Sousa-Pinto B. et al. Self-expandable metal stents in esophageal cancer before preoperative neoadjuvant therapy: efficacy, safety, and long-term outcomes. Surg Endosc 2020; 35: 5130-5139
• 10 Evans JA, Early DS, Chandraskhara V. et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013; 77: 328-334
• 11 Ogilvie A, Dronfield M, Ferguson R. et al. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 1982; 23: 1060-1067
• 12 Diamantis G, Scarpa M, Bocus P. et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol 2011; 17: 144
• 13 Madhusudhan C, Saluja SS, Pal S. et al. Palliative stenting for relief of dysphagia in patients with inoperable esophageal cancer: impact on quality of life. Dis Esophagus 2009; 22: 331-336
• 14 Wilkes EA, Jackson LM, Cole AT. et al. Insertion of expandable metallic stents in esophageal cancer without fluoroscopy is safe and effective: a 5-year experience. Gastrointest Endosc 2007; 65: 923-929
• 15 Mwachiro MM, Parker RK, Chepkwony R. et al. Esophageal stent placement without optical or fluoroscopic visualization. VideoGIE 2017; 2: 309-311
• 16 Chandan S, Mohan BP, Khan SR. et al. Clinical efficacy and safety of palliative esophageal stenting without fluoroscopy: a systematic review and meta-analysis. Endosc Int Open 2020; 8: E944
• 17 Abdelshafy M, Omar MA, Bary MA. et al. Self-expandable metal stent for palliation of malignant dysphagia & quality of life improvement in advanced cancer esophagus: Upper Egypt experience. J Egyptian Soc Cardio-Thorac Surgery 2017; 25: 262-269
• 18 Siddiqui AA, Ansari S, Ghouri MA. et al. Self expandable metallic stent endoscopic insertion in esophageal cancer. J Pak Med Assoc 2010; 20: 502-505
• 19 Hernandez LJ, Jacobson JW, Harris MS. Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures. Gastrointest Endosc 2000; 51: 460-462
• 20 Adler D. Esophageal stents: placement, complications, tips, and tricks. Video J Encyclopedia GI Endosc 2013; 1: 66-68
• 21 Boyce Jr. HW. Palliation of dysphagia of esophageal cancer by endoscopic lumen restoration techniques: proper management of dysphagia due to esophageal carcinoma should include palliative methods. Cancer Control 1999; 6: 73-83
• 22 Parker RK, Dawsey SM, Abnet CC. et al. Frequent occurrence of esophageal cancer in young people in western Kenya. Dis Esophagus 2010; 23: 128-135
• 23 Parker RK, White RE, Topazian M. et al. Stents for proximal esophageal cancer: A case-control study. Gastrointest Endosc 2011; 73: 1098-1105
• 24 Włodarczyk JR, Kużdżał J. Stenting in palliation of unresectable esophageal cancer. World J Surgery 2018; 42: 3988-3996
• 25 Parker RK, Mwachiro MM, Topazian HM. et al. Gastrointestinal endoscopy experience of surgical trainees throughout rural Africa. Surg Endosc 2020; 35: 6708-6716
• 26 Mohammad NH, Bernards N, van Putten M. et al. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. Europ J Cancer 2017; 78: 28-36
• 27 Burstow M, Kelly T, Panchani S. et al. Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis. Dis Esophagus 2009; 22: 519-525
• 28 Bergquist H, Wenger U, Johnsson E. et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Di the Esophagus 2005; 18: 131-139
• 29 Selinger C, Ellul P, Smith P. et al. Oesophageal stent insertion for palliation of dysphagia in a District General Hospital: experience from a case series of 137 patients. QJM 2008; 101: 545-548
• 30 Homs MY, Steyerberg EW, Eijkenboom WM. et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-1504
• 31 Grooteman KV, Song LMWK, Vleggaar FP. et al. Non-adherence to the rule of 3 does not increase the risk of adverse events in esophageal dilation. Gastrointest Endosc 2017; 85: 332-337 e331
• 32 White RE, Mungatana C, Topazian M. Expandable stents for iatrogenic perforation of esophageal malignancies. J Gastrointest Surg 2003; 7: 715-719
• 33 Tulman AB, Boyce Jr HW. Complications of esophageal dilation and guidelines for their prevention. Gastrointest Endosc 1981; 27: 229-234
• 34 Turkyilmaz A, Eroglu A, Aydin Y. et al. Complications of metallic stent placement in malignant esophageal stricture and their management. Surg Laparosc Endosc Percutaneous Tech 2010; 20: 10-15
• 35 Reijm AN, Didden P, Schelling SJ. et al. Self-expandable metal stent placement for malignant esophageal strictures–changes in clinical outcomes over time. Endoscopy 2019; 51: 18-29